Skip to main content
Open Access Publications from the University of California
Notice: eScholarship will undergo scheduled maintenance from Tuesday, January 21 to Wednesday, January 22. Some functionality may not be available during this time. Learn more at eScholarship Support.
Download PDF
- Main
Long COVID After Bamlanivimab Treatment
- Evering, Teresa H;
- Moser, Carlee B;
- Jilg, Nikolaus;
- Yeh, Eunice;
- Sanusi, Busola;
- Wohl, David A;
- Daar, Eric S;
- Li, Jonathan Z;
- Klekotka, Paul;
- Javan, Arzhang Cyrus;
- Eron, Joseph J;
- Currier, Judith S;
- Hughes, Michael D;
- Smith, Davey M;
- Chew, Kara W;
- Hosey, Lara;
- Roa, Jhoanna;
- Patel, Nilam;
- Coombs, Robert;
- Greninger, Alexander;
- Degli-Angeli, Emily;
- Goecker, Erin;
- Daza, Glenda;
- Harb, Socorro;
- Dragavon, Joan;
- Aldrovandi, Grace;
- Murtaugh, William;
- Cooper, Marlene;
- Gutzman, Howard;
- Knowles, Kevin;
- Bowman, Rachel;
- Erhardt, Bill;
- Waring, Lorraine;
- Hessinger, Diane;
- Adams, Stacey;
- Kallianpur, Asha R
Published Web Location
https://doi.org/10.1093/infdis/jiad286Abstract
Background
Prospective evaluations of long COVID in outpatients with coronavirus disease 2019 (COVID-19) are lacking. We aimed to determine the frequency and predictors of long COVID after treatment with the monoclonal antibody bamlanivimab in ACTIV-2/A5401.Methods
Data were analyzed from participants who received bamlanivimab 700 mg in ACTIV-2 from October 2020 to February 2021. Long COVID was defined as the presence of self-assessed COVID symptoms at week 24. Self-assessed return to pre-COVID health was also examined. Associations were assessed by regression models.Results
Among 506 participants, median age was 51 years. Half were female, 5% Black/African American, and 36% Hispanic/Latino. At 24 weeks, 18% reported long COVID and 15% had not returned to pre-COVID health. Smoking (adjusted risk ratio [aRR], 2.41 [95% confidence interval {CI}, 1.34- 4.32]), female sex (aRR, 1.91 [95% CI, 1.28-2.85]), non-Hispanic ethnicity (aRR, 1.92 [95% CI, 1.19-3.13]), and presence of symptoms 22-28 days posttreatment (aRR, 2.70 [95% CI, 1.63-4.46]) were associated with long COVID, but nasal severe acute respiratory syndrome coronavirus 2 RNA was not.Conclusions
Long COVID occurred despite early, effective monoclonal antibody therapy and was associated with smoking, female sex, and non-Hispanic ethnicity, but not viral burden. The strong association between symptoms 22-28 days after treatment and long COVID suggests that processes of long COVID start early and may need early intervention.Clinical trials registration
NCT04518410.Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.
Main Content
For improved accessibility of PDF content, download the file to your device.
Enter the password to open this PDF file:
File name:
-
File size:
-
Title:
-
Author:
-
Subject:
-
Keywords:
-
Creation Date:
-
Modification Date:
-
Creator:
-
PDF Producer:
-
PDF Version:
-
Page Count:
-
Page Size:
-
Fast Web View:
-
Preparing document for printing…
0%